During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD; Petros Grivas, MD, PhD; Sia Daneshmand, MD; and Sam Chang, MD, MBA, discussed the latest updates in non-muscle invasive bladder cancer. Therapies under consideration included nadofaragene firadenovec, pembrolizumab, IL-15 superagonist, atezolizumab, TAR-200, TAR-210, and more. ...
The Uromigos Live & Unplugged: Bladder Cancer
Advertisement
The panel discussed the latest data and updates in frontline bladder cancer during a livestreamed session.
Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma.
Drs. Powles, Tawagi, and Berg highlight attempts to define 2L SOC options, as well IO rechallenging in bladder cancer.
Dr. Pedro Barata discusses his thoughts on the use of cisplatin in patients with bladder cancer, as well as CheckMate 901.
Dr. Vadim Koshkin gives his thoughts on the CheckMate 901 study and its data that were presented at the conference.
Dr. Petros Grivas discusses new bladder cancer data, including the TAR-200 delivery system and the SunRISe trials.
Patient advocate Mary Beth Ballard discusses how new research and data gives hope to patients with bladder cancer.
Dr. Gautam Jayram discusses his biggest takeaways from the event, including panels on non-muscle invasive bladder cancer.
Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC.
Dr. Karine Tawagi discusses her proposed trial on a phase 2 multi-arm parallel trial for metastatic UC.
Dr. O'Donnell shares his impression of the data at ESMO and offers a positive outlook on the future of UC.
Dr. Stephanie Berg describes her presentation given on second-line treatment for mUC during the Rising Stars panel.
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
Dr. Terence Friedlander provides his take on CheckMate 901 and the enfortumab vedotin/pembrolizumab combination.
Tom is joined by Drs. Chang, Daneshmand, and Grivas to discuss new therapies in NMIBC and BCG-refractory NMIBC.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
Advertisement
